Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the associations between patient out-of-pocket (OOP) costs and nonadherence to glucagon-like peptide 1 receptor agonists (GLP-1RA), and the consequent impact on adverse outcomes, including hospitalizations and emergency department (ED) visits. RESEARCH DESIGN AND METHODS: This retrospective cohort study used MarketScan Commercial data (2016–2021). The cohort included nonpregnant adults aged 18–64 years with type 2 diabetes who initiated GLP-1RA therapy. Participants were continuously enrolled in the same private insurance plan for 6 months before the prescription date and 1 year thereafter. Exposures included average first 30-day OOP costs for GLP-1RA, categorized into quartiles (lowest [Q1] to highest [Q4]). Primary outcomes were the annual proportion of days covered (PDC) for GLP-1RA and nonadherence, defined as PDC <0.8. Secondary outcomes included diabetes-related and all-cause hospitalizations and ED visits 1 year after GLP-1RA initiation. RESULTS: Among 61,907 adults who initiated GLP-1RA, higher 30-day OOP costs were associated with decreased adherence. Patients in the highest OOP cost quartile (Q4: $80–$3,375) had significantly higher odds of nonadherence (odds ratio [OR] 1.25; 95% CI 1.19–1.31) compared with those in Q1 ($0–$21). Nonadherence was linked to increased incidence rates of diabetes-related hospitalizations or ED visits (incidence rate ratio [IRR] 1.86; 95% CI 1.43–2.42), cumulative length of hospitalization (IRR 1.56; 95% CI 1.41–1.72), all-cause ED visits (IRR 1.38; 95% CI 1.32–1.45), and increased ED-related costs ($69.81, 95% CI $53.54–$86.08). CONCLUSIONS: Higher OOP costs for GLP-1RA were associated with reduced adherence and increased rates of adverse outcomes among patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A dose–response relationship exists between cost-sharing and adherence: patients in the highest out-of-pocket cost quartiles have significantly greater odds of nonadherence [57].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Charlson Comorbidity Index: A Critical Review of Clinimetric Properties
Charlson, M. E., Carrozzino, D., Guidi, J., & Patierno, C. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000521288 · Cited by 1,686
Carrera, P. M., Kantarjian, H. M., & Blinder, V. S. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21443 · Cited by 876
Eberly, L. A., Yang, L., Eneanya, N. D., Essien, U., Julien, H., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., Giri, J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.6139 · Cited by 350
Eberly, L. A., Yang, L., Essien, U. R., Eneanya, N. D., Julien, H. M., Luo, J., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., et al. (2021) · JAMA Health Forum · doi:10.1001/jamahealthforum.2021.4182 · Cited by 288
Association of shared decision-making on patient-reported health outcomes and healthcare utilization
Hughes, T. M., Merath, K., Chen, Q., Sun, S., Palmer, E., Idrees, J. J., Okunrintemi, V., Squires, M., Beal, E. W., & Pawlik, T. M. (2018) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2018.01.011 · Cited by 259
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259
Cost-Related Insulin Underuse Among Patients With Diabetes
Herkert, D., Vijayakumar, P., Luo, J., Schwartz, J. I., Rabin, T. L., DeFilippo, E., & Lipska, K. J. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.5008 · Cited by 230
Han, S. H., Safeek, R., Ockerman, K., Trieu, N., Mars, P., Klenke, A., Furnas, H., & Sorice-Virk, S. (2023) · Aesthetic Surgery Journal · doi:10.1093/asj/sjad211 · Cited by 210
A Policy Prescription for Reducing Health Disparities—Achieving Pharmacoequity
Essien, U. R., Dusetzina, S. B., & Gellad, W. F. (2021) · JAMA · doi:10.1001/jama.2021.17764 · Cited by 183
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes
Chuang, M.-H., Chen, J.-Y., Wang, H.-Y., Jiang, Z.-H., & Wu, V.-C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.27258 · Cited by 133
Whitley, H. P., Trujillo, J. M., & Neumiller, J. J. (2023) · Clinical Diabetes · doi:10.2337/cd23-0023 · Cited by 132
Proportion of days covered as a measure of medication adherence
Loucks, J., Zuckerman, A. D., Berni, A., Saulles, A., Thomas, G., & Alonzo, A. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab392 · Cited by 94
Yeo, Y. H., Rezaie, A., Hsieh, T. Y.-J., Hu, X., Gaddam, S., Ma, K. S.-K., Gastrointestinal Motility and Metabolic Pharmacoepidemiology Group, Mohamed, G., Lee, G. Y., Huang, P.-C., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m24-0019 · Cited by 90
Choi, J. G., Winn, A. N., Skandari, M. R., Franco, M. I., Staab, E. M., Alexander, J., Wan, W., Zhu, M., Huang, E. S., Philipson, L., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-2941 · Cited by 87
Luo, J., Feldman, R., Callaway Kim, K., Rothenberger, S., Korytkowski, M., Hernandez, I., & Gellad, W. F. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.17886 · Cited by 82
Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review
Boyle, J. G., Livingstone, R., & Petrie, J. R. (2018) · Clinical Science · doi:10.1042/cs20171299 · Cited by 78
Ubel, P. A., Zhang, C. J., Hesson, A., Davis, J. K., Kirby, C., Barnett, J., & Hunter, W. G. (2016) · Health Affairs · doi:10.1377/hlthaff.2015.1280 · Cited by 70
Essien, U. R., Singh, B., Swabe, G., Johnson, A. E., Eberly, L. A., Wadhera, R. K., Breathett, K., Vaduganathan, M., & Magnani, J. W. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.16290 · Cited by 69
McCoy, R. G., Van Houten, H. K., Karaca-Mandic, P., Ross, J. S., Montori, V. M., & Shah, N. D. (2021) · Diabetes Care · doi:10.2337/dc20-2977 · Cited by 57
Kazi, D. S., DeJong, C., Chen, R., Wadhera, R. K., & Tseng, C. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.414 · Cited by 41
Decision-Making Experiences Of Consumers Choosing Individual-Market Health Insurance Plans
Hero, J. O., Sinaiko, A. D., Kingsdale, J. M., Gruver, R. S., & Galbraith, A. A. (2019) · Health Affairs · doi:10.1377/hlthaff.2018.05036 · Cited by 35
Strategies to Help Patients Navigate High Prescription Drug Costs
Lalani, H. S., Hwang, C. S., Kesselheim, A. S., & Rome, B. N. (2024) · JAMA · doi:10.1001/jama.2024.17275 · Cited by 32
Real-Time Benefit Tools for Drug Prices
Everson, J., Frisse, M. E., & Dusetzina, S. B. (2019) · JAMA · doi:10.1001/jama.2019.16434 · Cited by 31
Hyperlipidemia and Medical Expenditures by Cardiovascular Disease Status in US Adults
Zhang, D. “., Wang, G., Fang, J., & Mercado, C. I. (2016) · Medical Care · doi:10.1097/mlr.0000000000000663 · Cited by 28
Self-citationBays, H. E., Fitch, A., Francavilla Brown, C., Younglove, C., Christensen, S. M., & Alexander, L. C. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100122 · Cited by 16
Shao, H., Laxy, M., Benoit, S. R., Cheng, Y. J., Gregg, E. W., & Zhang, P. (2021) · Diabetes Care · doi:10.2337/dc20-2871 · Cited by 15
Impact of Real-Time Benefit Tools on Patients’ Access to Medications: A Retrospective Cohort Study
Bhardwaj, S., Merrey, J. W., Bishop, M. A., Yeh, H., & Epstein, J. A. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.06.017 · Cited by 15
Blumberg, S. J., & Luke, J. V. (2022) · doi:10.15620/cdc:121999 · Cited by 13
Management of Chronic Hypertension During Pregnancy
Chandrasekaran, S., Badell, M. L., & Jamieson, D. J. (2022) · JAMA · doi:10.1001/jama.2022.3919 · Cited by 12
Impact of Co-pay Assistance on Patient, Clinical, and Economic Outcomes
Parekh, K. (2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.89151 · Cited by 12
Zhang, D. “., Lee, J. S., Popoola, A., Lee, S. J., Jackson, S. L., Pollack, L. M., Dong, X., Therrien, N. L., & Luo, F. (2024) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.123.010739 · Cited by 11
Self-citationSinaiko, A. D., Kingsdale, J. M., & Galbraith, A. A. (2017) · Medical Care Research and Review · doi:10.1177/1077558717718625 · Cited by 8
Zhang, D. “., Xu, J., Hall, D. B., Chen, X., Chen, M., Divers, J., Wei, J., Rajbhandari‐Thapa, J., Wright, D. R., Arabadjian, M. E., et al. (2024) · American Journal of Hypertension · doi:10.1093/ajh/hpae062 · Cited by 5
Self-citationLeeolou, M. C., Jia, J. L., Pham, D. L., & Sarin, K. Y. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.10.062 · Cited by 2
Research works printed but not linked: 2
- U.S. Food and Drug Administration, 2023, Medications containing semaglutide marketed for type 2 diabetes or weight loss. January, 202
- Schulte, 2023, Association of insurance characteristics and persistence with anti-obesity and GLP-1 RA medications, Obesity, 31, 36
Cited by
Dhippayom, T., Meraz, M., Lee, H., Hur, C., Inadomi, J. M., Veettil, S. K., Dunn, J. D., & Chaiyakunapruk, N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70322 · Cited by 14
“39,40 These real-world adherence issues may affect the actual effectiveness and economic value of GLP-1RAs, particularly if early discontinuation limits the duration of health benefits.”
Xie, Y., Choi, T., & Al-Aly, Z. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002150 · Cited by 8
“Veterans Affairs operates the largest nationally integrated health-care system in the US, providing care to more than nine million veterans at 1380 healthcare facilities, including 170 medical centres and 1193 outpatient sites.”
Wanner, C., Cosentino, F., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Boll, H. N., Brosius, F. C., Busetto, L., Ceriello, A., Gavin, J. R., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03098-z · Cited by 4
“Even when evidence is robust, high out-of-pocket costs and reimbursement restrictions within coverage policies can prevent equitable and sustained access [48–50].”
Bariatric Surgery in the Era of GLP1RA: A Narrative Review
Muhundan, M., & Dash, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03494-7 · Cited by 2
“Medication costs have been correlated with significant impacts on GLP1RA adherence in the USA [96].”
Racial and demographic disparities in glp-1ra use among breast cancer patients with Type 2 Diabetes
Hundal, J., Ashruf, O. S., Li, H., Basen‐Engquist, K., Kaelber, D. C., & Sukumar, J. S. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00844-6 · Cited by 6
Metadata
- Authors
- Zhang, D., Gencerliler, N., Mukhopadhyay, A., Blecker, S., Grams, M. E., Wright, D. R., Wang, V. H.-C., Rajan, A., Butt, E., Shin, J.-I., Xu, Y., Chhabra, K. R., & Divers, J.
- Affiliations
- NYU Grossman Long Island School of Medicine (US)
- New York University (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Bellevue Hospital Center (US)
- Corresponding author
- Zhang, Donglan
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2025-04-09
- Volume
- 48
- Issue
- 8
- Pages
- 1329-1336
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC13053885
- OpenAlex
- W4409283716
- Cited by
- 14
- References
- 35
- Citations by year
- 2026: 10 · 2025: 4
- FWCI
- 18.67
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Doucette Innovation Fund
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Keywords
- patient cost sharing, out-of-pocket costs, GLP-1 receptor agonists, medication adherence, type 2 diabetes, hospitalization, emergency department visits, health care costs, insurance coverage, proportion of days covered
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adolescent, Adult, Diabetes Mellitus, Type 2, Emergency Service, Hospital, Female, Hospitalization, Humans, Hypoglycemic Agents, Male, Middle Aged, Retrospective Studies, Cost Sharing, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.